Association of human leucocyte antigen Class I (HLA-A and HLA-B) with chronic hepatitis C virus infection in Egyptian patients.
Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, ranging from 6% to 28% with an average of approximately 13.8% in the general population. It has been reported that human leucocyte antigen (HLA) alleles are associated with the outcome of HCV infection, but this associations showed ethnic and geographical differences. The objective of this study is to investigate the association between the frequencies of HLA Class I and chronic HCV infection in Egyptian patients and to find out whether there is a relation between certain HLA Class I antigens and HCV viral load, degree of fibrosis, activity and alanine aminotransferase (ALT) level. A case control study was conducted on 100 patients with chronic HCV infection and 150 healthy controls. HLA-A and HLA-B typing by complement-dependent micro-lympho-cytotoxicity assay was performed for both groups. HLA-A11 antigen was significantly increased in patients with chronic HCV infection versus controls (OR 3.98; 95% CI = 1.85-8.89; P = 0.001; and Pc = 0.021). HLA-B12, HLA-B13, HLA-B17 and HLA-B40 were higher in patients, and HLA-A32 and HLA-B14 were higher in controls, although the significance was lost after correction for multiple testing. HLA-A9 was significantly associated with low viral load (P = 0.008, Pc = 0.048). The results of this work implicate that HLA-A11 antigen may influence chronic HCV infection and may play a role in viral persistence. Different HLA Class I antigens are not associated with degree of liver fibrosis, grades of activity or level of ALT. However, HLA-A9 is associated with low HCV viral load in chronic HCV Egyptian patients.
Clinical Immunology Unit, Clinical Pathology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt. youssefmosaad@yahoo.com
Y M
YM
Mosaad
R E
RE
Farag
M M
MM
Arafa
S
S
Eletreby
H A
HA
El-Alfy
B S
BS
Eldeek
Z M
ZM
Tawhid
D000410:Alanine Transaminase / Q000097:blood; D016022:Case-Control Studies; D004534:Egypt; D015234:HLA-A Antigens / Q000276:immunology* / Q000502:physiology; D059870:HLA-A11 Antigen; D015235:HLA-B Antigens / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000276:immunology* / Q000473:pathology / Q000821:virology; D006801:Humans; D008103:Liver Cirrhosis / Q000473:pathology; D019562:Viral Load
D015234:HLA-A Antigens; D059870:HLA-A11 Antigen; D015235:HLA-B Antigens; D000410:Alanine Transaminase